Atossa Therapeutics, Inc. (FRA:YAG)
Germany · Delayed Price · Currency is EUR | Market Cap | 22.70M -73.0% |
| Revenue (ttm) | n/a |
| Net Income | -33.01M |
| EPS | -3.80 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 2.240 |
| Previous Close | 2.240 |
| Day's Range | 2.240 - 2.240 |
| 52-Week Range | 1.520 - 16.230 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
About Atossa Therapeutics
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January ... [Read more]
News
Atossa Therapeutics reports Q2 EPS (95c) vs. (98c) last year
“During the quarter, we executed well across the business,” stated Dr. Steven Quay, M.D., Ph.D., Atossa Therapeutics (ATOS)’ President and Chief Executive Officer. “We continued to advance the scienti...
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other area...
Atossa Therapeutics Quarterly report: Q2 2026
Atossa Therapeutics has published its Q2 2026 quarterly earnings report on August 7, 2026.
Atossa Therapeutics Earnings release: Q2 2026
Atossa Therapeutics released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
Atossa Therapeutics sees opportunities for (Z)-endoxifen beyond breast cancer
13:00 EDT Atossa Therapeutics (ATOS) sees opportunities for (Z)-endoxifen beyond breast cancer
Meet Atossa Therapeutics: Fly Exclusive with CFO Mark Daniel
In an exclusive interview, Atossa Therapeutics‘…
Atossa Therapeutics’ (Z)-endoxifen compounds show anti-breast cancer action
Atossa Therapeutics (ATOS) announced the publication of a peer-reviewed preclinical study in npj Breast Cancer evaluating five novel chemical entities structurally related to (Z)-endoxifen. The study ...
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with activity in ESR1-mutant models Findings suggest potential for combination with abemaciclib SEATTLE,...
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Potential Therapeutic Strategy for Estrogen-Driven Pathology in McCune-Albright syndrome SEATTLE, July 2...
Atossa Therapeutics initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw initiated coverage of Atossa Therapeutics (ATOS) with a Buy rating and $12 price target citing the company’s “uniquely versatile” next-generation estrogen receptor modulator/degrader ...
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants SEATTLE, June 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasd...
Atossa Therapeutics announces registered direct offering of up to $16.5M
Atossa Therapeutics (ATOS) announced that it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 1,363,638 shares of its common stock, par value…
Atossa Therapeutics announces $16.5M registered direct offering
Atossa Therapeutics (ATOS) announced that it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 1,363,638 shares of its common stock, par value…
Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds
$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants SEATTLE, June 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasd...
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial
Preclinical Data Abstract Demonstrates Robust Estrogen Receptor (ER) Inhibition in ESR1-Mutant Breast Cancer Models at Clinically Relevant Concentrations Trial-in-Progress Abstract Details Ongoing Pha...
Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy
Review article accepted for publication in Degenerative Neurological and Neuromuscular Disease and builds on Atossa's previously published Duchenne Muscular Dystrophy (DMD) research SEATTLE, May 20, 2...
Atossa Therapeutics Transcript: Status update
Adaptive platform trials like I-SPY are accelerating breast cancer drug development, focusing on early endpoints and individualized therapies. Endoxifen demonstrates strong efficacy and tolerability, with ongoing trials exploring its use in combination regimens. Regulatory engagement and personalized prevention strategies are driving faster, more patient-centered progress.
Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer
Event to feature Dr. Laura Esserman, internationally recognized surgical oncologist, breast cancer expert, and founder and principal investigator of the I-SPY Trials SEATTLE, May 14, 2026 /PRNewswire/...
Atossa Therapeutics reports Q1 EPS ($1.11) vs. (78c) last year
“During the quarter, we made meaningful progress advancing our (Z)-endoxifen development strategy across both oncology and rare disease indications,” stated Dr. Steven Quay, M.D., Ph.D., Atossa Therap...
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
SEATTLE, May 8, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas...
Atossa Therapeutics Quarterly report: Q1 2026
Atossa Therapeutics has published its Q1 2026 quarterly earnings report on May 8, 2026.
Atossa Therapeutics Earnings release: Q1 2026
Atossa Therapeutics released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Atossa Therapeutics’ Endoxifen shows breast cancer risk prevention in trial
Atossa Therapeutics (ATOS) announced the publication of results from the KARISMA Endoxifen trial in the Journal of the National Cancer Institute. The Phase 2 study evaluated daily oral Endoxifen and…
Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women
Peer-reviewed data support (Z)-endoxifen's (Endoxifen) potential as a differentiated breast cancer risk prevention candidate by marked reduction of mammographic breast density (MBD) Doses of both 1 mg...
Atossa Therapeutics says FDA grants RPD to (Z)-endoxifen to treat MAS
Atossa Therapeutics (ATOS) announced that the U.S. FDA has granted Rare Pediatric Disease designation to (Z)-endoxifen for the treatment of McCune-Albright Syndrome in females. RPD designation is gran...